Aldeyra Therapeuticsincis A Biotechnology Company Based In Lexingtonmassachusettsestablished In 2004The Company Focuses On Developing Innovative Therapies For Immune Mediated And Metabolic Diseasesaldeyra Employs Unique Mechanisms To Address Unmet Medical Needsparticularly In Inflammatory And Metabolic Disordersby Targeting Reactive Aldehyde Speciesrasp Which Are Linked To Various Diseases The Company S Product Pipeline Includes Several Promising Candidatesreproxalap Is A First In Class Rasp Modulator In Late Stage Development For Dry Eye Disease And Allergic Conjunctivitisadx 629 Is An Oral Rasp Modulator In Clinical Trials For Moderate Alcohol Associated Hepatitis And Sja Gren Larsson Syndromeother Investigational Therapies Target Conditions Such As Atopic Dermatitisretinitis Pigmentosaand Obesityaldeyra S Approach Aims To Optimize Multiple Biological Pathways While Minimizing Toxicitysetting It Apart From Traditional Therapieswith A Small Team Of Nine Employeesaldeyra Operates In The U Sand Germanycompeting In A Market With Larger Firms
